1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

Saroglitazar Magnesium 

Cat. No.: HY-19937A Purity: 98.85%
Handling Instructions

Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.

For research use only. We do not sell to patients.
Saroglitazar Magnesium Chemical Structure

Saroglitazar Magnesium Chemical Structure

CAS No. : 1639792-20-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 714 In-stock
1 mg USD 180 In-stock
5 mg USD 468 In-stock
10 mg USD 720 In-stock
25 mg USD 1440 In-stock
50 mg USD 2160 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Saroglitazar Magnesium:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.

IC50 & Target

EC50: 0.65 pM (hPPARα, HepG2 cell); 3 nM (hPPARγ, HepG2 cell)[1]

In Vivo

In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes[1].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.1094 mL 5.5468 mL 11.0936 mL
5 mM 0.2219 mL 1.1094 mL 2.2187 mL
10 mM 0.1109 mL 0.5547 mL 1.1094 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration
[1]

Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage[1].

Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3,1, and 3 mg/kg per day) or pioglitazone (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, free fatty acid (FFA), and insulin levels[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

901.42

Formula

C₅₀H₅₆N₂O₈S₂Mg

CAS No.

1639792-20-3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

  • 竞价别名

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Saroglitazar Magnesium
Cat. No.:
HY-19937A
Quantity: